ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - sirolimus - תמיסה (פומי) - sirolimus 1 mg/ml - sirolimus - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.

ישראל - עברית - Ministry of Health

vitamed pharmaceutical industries ltd - amoxicillin as trihydrate - אבקה להכנת תרחיף - amoxicillin as trihydrate 250 mg / 5 ml - amoxicillin

ישראל - עברית - Ministry of Health

unipharm ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 10 mg - pravastatin

ישראל - עברית - Ministry of Health

bristol - myers squibb, israel - atazanavir as sulfate - קפסולות - atazanavir as sulfate 300 mg - atazanavir

ישראל - עברית - Ministry of Health

aop orphan pharmaceuticals israel ltd, israel - ropeginterferon alfa-2b - תמיסה להזרקה - ropeginterferon alfa-2b 500 mcg/ml - ropeginterferon alfa-2b

ישראל - עברית - Ministry of Health

aop orphan pharmaceuticals israel ltd, israel - ropeginterferon alfa-2b - תמיסה להזרקה - ropeginterferon alfa-2b 1000 mcg/ml - ropeginterferon alfa-2b

ישראל - עברית - Ministry of Health

novartis israel ltd - glycopyrronium as bromide; indacaterol as acetate; mometasone furoate - קפסולה קשיחה - mometasone furoate 160 mcg; glycopyrronium as bromide 50 mcg; indacaterol as acetate 150 mcg - mometasone

ישראל - עברית - Ministry of Health

neopharm scientific ltd - catumaxomab 100 mcg/ml - concentrate for solution for infusion - catumaxomab - intraperitoneal treatment of malignant ascites in patients with epcam-positive carcinomas where standard therapy is not available or no longer feasible.

ישראל - עברית - Ministry of Health

rafa laboratories ltd - calfactant as phospholipid - תרחיף - calfactant as phospholipid 35 mg/ml - lung surfactants - infasurf is indicated for the prevention of respiratory distress syndrome (rds) in premature infants at high risk for rds and for the treatment ("rescue") of premature infants who develop rds. infasurf decreases the incidence of rds mortality due to rds and air leaks associated with rds. prophylaxis : prophylaxis therapy at birth with infasurf is indicated for premature infants <29 weeks of gestational age at significant risk for rds. infasurf prophylaxis should be administered as soon as possible preferably within 30 minutes after birth. treatment: infasurf therapy is indicated for infants 72 hours of age with rds (confirmed by clinical and radiologic findings) and requiring endotracheal intubation.

ישראל - עברית - Ministry of Health

שמן מרוקאי ישראל בעמ - טיפול לקרקפת יבשה